Amit G Pandya

List of Publications by Citations

134 papers	2,951 citations	30 h-index	53 g-index
145 ext. papers	3,835 ext. citations	3.9 avg, IF	5.48 L-index

#	Paper	IF	Citations
134	Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. *Journal of the American Academy of Dermatology*, **2008**, 58, 1043-6	4.5	372
133	Melasma: a comprehensive update: part I. *Journal of the American Academy of Dermatology*, **2011**, 65, 689-697	4.5	187
132	Melasma: a comprehensive update: part II. *Journal of the American Academy of Dermatology*, **2011**, 65, 699-714	4.5	161
131	New discoveries in the pathogenesis and classification of vitiligo. *Journal of the American Academy of Dermatology*, **2017**, 77, 1-13	4.5	155
130	Disorders of hyperpigmentation. *Dermatologic Clinics*, **2000**, 18, 91-8, ix	4.2	147
129	Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. *Journal of the American Academy of Dermatology*, **2011**, 64, 78-83, 83.e1-2	4.5	143
128	Treatment of melasma with topical agents, peels and lasers: an evidence-based review. *American Journal of Clinical Dermatology*, **2013**, 14, 359-76	7.1	91
127	Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. *Science Translational Medicine*, **2018**, 10,	17.5	87
126	Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease. *Journal of Investigative Dermatology*, **2017**, 137, 350-358	4.3	83
125	Current and emerging treatments for vitiligo. *Journal of the American Academy of Dermatology*, **2017**, 77, 17-29	4.5	82
124	Efficacy of glycolic acid peels in the treatment of melasma. *Archives of Dermatology*, **2002**, 138, 1578-82		78
123	Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. *International Journal of Dermatology*, **2003**, 42, 966-72	1.7	74
122	Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus. *Pigment Cell and Melanoma Research*, **2015**, 28, 363-9	4.5	61
121	Melasma in Latina patients: cross-cultural adaptation and validation of a quality-of-life questionnaire in Spanish language. *Journal of the American Academy of Dermatology*, **2006**, 55, 59-66	4.5	61
120	Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. *Lancet, The*, **2020**, 396, 110-120	40	59
119	Vitiligo is not a cosmetic disease. *Journal of the American Academy of Dermatology*, **2015**, 73, 883-5	4.5	55
118	Melasma: clinical diagnosis and management options. *Australasian Journal of Dermatology*, **2015**, 56, 151-63	1.3	53

117	Confetti-like depigmentation: A potential sign of rapidly progressing vitiligo. *Journal of the American Academy of Dermatology*, **2015**, 73, 272-5	4.5	50
116	Increasing racial and ethnic diversity in dermatology: A call to action. *Journal of the American Academy of Dermatology*, **2016**, 74, 584-7	4.5	50
115	Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. *Journal of the American Academy of Dermatology*, **2018**, 78, 363-369	4.5	47
114	Lichen planus pigmentosus and its variants: review and update. *International Journal of Dermatology*, **2018**, 57, 505-514	1.7	42
113	Prevalence of self-diagnosed melasma among premenopausal Latino women in Dallas and Fort Worth, Tex. *Archives of Dermatology*, **2007**, 143, 424-5		42
112	A randomized, double-blinded, placebo-controlled trial of oral Polypodium leucotomos extract as an adjunct to sunscreen in the treatment of melasma. *JAMA Dermatology*, **2013**, 149, 981-3	5.1	41
111	Oral Tranexamic Acid for the Treatment of Melasma: A Review. *Dermatologic Surgery*, **2018**, 44, 814-825	1.7	38
110	A global consensus statement on ashy dermatosis, erythema dyschromicum perstans, lichen planus pigmentosus, idiopathic eruptive macular pigmentation, and Riehl's melanosis. *International Journal of Dermatology*, **2019**, 58, 263-272	1.7	37
109	Melasma treated with hydroquinone, tretinoin, and a fluorinated steroid. *International Journal of Dermatology*, **2001**, 40, 212-5	1.7	35
108	A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women. *Journal of the American Academy of Dermatology*, **2010**, 63, 1030-5	4.5	33
107	Melasma Treatment: An Evidence-Based Review. *American Journal of Clinical Dermatology*, **2020**, 21, 173-225	7.1	31
106	Diversity in dermatology: Roadmap for improvement. *Journal of the American Academy of Dermatology*, **2018**, 79, 337-341	4.5	30
105	Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept. *Journal of the European Academy of Dermatology and Venereology*, **2009**, 23, 483-4	4.6	30
104	Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. *Journal of the American Academy of Dermatology*, **2006**, 54, 1083-8	4.5	29
103	Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. *Journal of the American Academy of Dermatology*, **2010**, 62, 962-7	4.5	28
102	Melasma quality of life measures. *Dermatologic Clinics*, **2012**, 30, 269-80, viii	4.2	27
101	Reliability assessment and validation of the postacne hyperpigmentation index (PAHPI), a new instrument to measure postinflammatory hyperpigmentation from acne vulgaris. *Journal of the American Academy of Dermatology*, **2014**, 70, 108-14	4.5	25
100	Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference. *Pigment Cell and Melanoma Research*, **2017**, 30, 28-40	4.5	23

99	Presentations, Signs of Activity, and Differential Diagnosis of Vitiligo. *Dermatologic Clinics*, **2017**, 35, 135-144	4.2	20
98	International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation. *British Journal of Dermatology*, **2019**, 180, 574-579	4	18
97	A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo. *Journal of the American Academy of Dermatology*, **2019**, 81, 646-648	4.5	17
96	Cultural competence for the 21st century dermatologist practicing in the United States. *Journal of the American Academy of Dermatology*, **2017**, 77, 1159-1169	4.5	16
95	Defining early mycosis fungoides: validation of a diagnostic algorithm proposed by the International Society for Cutaneous Lymphomas. *Journal of Cutaneous Pathology*, **2015**, 42, 318-28	1.7	16
94	What's new in objective assessment and treatment of facial hyperpigmentation?. *Dermatologic Clinics*, **2014**, 32, 123-35	4.2	15
93	Beware of underlying malignancy: acquired ichthyosis. *American Journal of Medicine*, **2014**, 127, 202-4	2.4	14
92	Interpretability of the Modified Melasma Area and Severity Index (mMASI). *JAMA Dermatology*, **2016**, 152, 1051-2	5.1	13
91	Rituximab in the treatment of 38 patients with Pemphigus with long-term follow-up. *Journal of the European Academy of Dermatology and Venereology*, **2016**, 30, 1050-2	4.6	12
90	Alkylating agents. *Dermatologic Therapy*, **2002**, 15, 317-324	2.2	11
89	Addition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and topical steroids helps arrest disease activity in patients with vitiligo. *British Journal of Dermatology*, **2019**, 180, 193-194	4	10
88	US Dermatology Department Faculty Diversity Trends by Sex and Underrepresented-in-Medicine Status, 1970 to 2018. *JAMA Dermatology*, **2020**, 156, 280-287	5.1	9
87	Cross-cultural validation of a short-form of the Vitiligo Impact Patient scale (VIPs). *Journal of the American Academy of Dermatology*, **2019**, 81, 1107-1114	4.5	9
86	The majority of patients presenting with vitiligo have a clinical sign of activity. *Journal of the American Academy of Dermatology*, **2017**, 77, 774-775	4.5	9
85	Improvement of idiopathic acanthosis nigricans with a triple combination depigmenting cream. *Journal of the European Academy of Dermatology and Venereology*, **2009**, 23, 486-7	4.6	9
84	Development and validation of a Hindi language health-related quality of life questionnaire for melasma in Indian patients. *Indian Journal of Dermatology, Venereology and Leprology*, **2016**, 82, 16-22	0.8	9
83	A cross-sectional, comparative study of home vs in-office NB-UVB phototherapy for vitiligo. *Photodermatology Photoimmunology and Photomedicine*, **2017**, 33, 282-283	2.4	8
82	Cicatricial pemphigoid of the scalp mimicking discoid lupus erythematosus. *Journal of the American Academy of Dermatology*, **2011**, 65, 886-887	4.5	8

81	Association of Quality of Life and Location of Lesions in Patients With Vitiligo. *JAMA Dermatology*, **2017**, 153, 341-342	5.1	7
80	Validation of a physician global assessment tool for vitiligo extent: Results of an international vitiligo expert meeting. *Pigment Cell and Melanoma Research*, **2019**, 32, 728-733	4.5	7
79	The effect of melasma on self-esteem: A pilot study. *International Journal of Women's Dermatology*, **2018**, 4, 38-42	2	7
78	Deferasirox for porphyria cutanea tarda: a pilot study. *Archives of Dermatology*, **2012**, 148, 898-901		7
77	scRNA-seq of human vitiligo reveals complex networks of subclinical immune activation and a role for CCR5 in T function. *Science Translational Medicine*, **2021**, 13, eabd8995	17.5	7
76	Psychosocial Effects of Vitiligo: A Systematic Literature Review. *American Journal of Clinical Dermatology*, **2021**, 22, 757-774	7.1	7
75	A pilot study to determine vitiligo target size using a computer-based image analysis program. *Journal of the American Academy of Dermatology*, **2015**, 73, 342-5	4.5	6
74	Randomised, controlled, double-blind study of combination therapy of oral tranexamic acid and topical hydroquinone in the treatment of melasma. *Australasian Journal of Dermatology*, **2020**, 61, 237-242	1.3	5
73	Skin diseases in rural Yucatan, Mexico. *International Journal of Dermatology*, **2012**, 51, 823-8	1.7	5
72	Seborrheic dermatitis or tinea capitis: don't be fooled. *International Journal of Dermatology*, **1998**, 37, 827-8	1.7	5
71	Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial. *Journal of the American Academy of Dermatology*, **2021**,	4.5	5
70	Use of Suction Blisters for Noncultured Epidermal Suspension Grafting in Patients With Vitiligo. *Dermatologic Surgery*, **2016**, 42, 688-91	1.7	5
69	Patient satisfaction with different treatment modalities for vitiligo. *Journal of the American Academy of Dermatology*, **2015**, 72, 732-3	4.5	4
68	Lack of correlation of the patient-derived Vitiligo Disease Activity Index with the clinician-derived Vitiligo Area Scoring Index. *Journal of the American Academy of Dermatology*, **2018**, 78, 1015-1016	4.5	4
67	Acne Knowledge of Hispanic Parents of Teenagers with Mild to Moderate Acne. *Pediatric Dermatology*, **2016**, 33, e292-3	1.9	4
66	Assessment of vitiligo severity: patient-reported estimates are not accurate. *British Journal of Dermatology*, **2015**, 173, 1325-6	4	4
65	Acute generalized exanthematous pustulosis (AGEP) caused by telavancin. *Journal of the American Academy of Dermatology*, **2011**, 65, e100-e101	4.5	4
64	Noncultured epidermal suspension grafting using suction blisters as donor tissue for vitiligo. *Journal of the American Academy of Dermatology*, **2019**, 80, 1152-1154	4.5	3

63	Diversity in the dermatology workforce. *Seminars in Cutaneous Medicine and Surgery*, **2016**, 36, 242-245	1.4	3
62	Prevalence of Vitiligo Among Adults in the United States. *JAMA Dermatology*, **2021**,	5.1	3
61	Implications of increasing publication trends in dermatology on individuals from disadvantaged backgrounds and those without a home dermatology program. *Journal of the American Academy of Dermatology*, **2021**, 84, e109-e110	4.5	3
60	What are the barriers faced by under-represented minorities applying to dermatology? A qualitative cross-sectional study of applicants applying to a large dermatology residency program. *Journal of the American Academy of Dermatology*, **2020**, 83, 1770-1773	4.5	2
59	Evidence Toward Integrated Management of Vitiligo, Combining Ayurveda and Homeopathy with Modern Dermatology **2018**, 159-169		2
58	Serving the underserved: creating a low-cost sunscreen with natural ingredients for humanitarian medical trips to the developing world. *British Journal of Dermatology*, **2014**, 171, 415-7	4	2
57	Quality of life in patients with vitiligo using the Short Form-36. *British Journal of Dermatology*, **2017**, 177, 1764-1766	4	2
56	Topical PUVA for post-inflammatory hypopigmentation. *Journal of the European Academy of Dermatology and Venereology*, **2011**, 25, 742-3	4.6	2
55	Reply to the comment on "What are the barriers faced by underrepresented minorities applying to dermatology? A qualitative cross-sectional study of applicants applying to a large dermatology residency program". *Journal of the American Academy of Dermatology*, **2020**, 83, e423	4.5	2
54	Transcultural assessment of quality of life in patients with vitiligo. *Journal of the American Academy of Dermatology*, **2021**,	4.5	2
53	Surgical Management of Leukotrichia **2018**, 401-405		2
52	A Missed Opportunity to Discuss Racial and Gender Bias in Dermatology. *JAMA Dermatology*, **2017**, 153, 110-111	5.1	1
51	The Importance of Patient Registries in Skin of Color. *Journal of Investigative Dermatology Symposium Proceedings*, **2017**, 18, S31-S33	1.1	1
50	Future Directions in the Treatment of Vitiligo **2018**, 475-489		1
49	Narrow-Band Ultraviolet B Phototherapy in Vitiligo **2018**, 91-103		1
48	Immunomodulators and Immunosuppressives in Vitiligo Treatment **2018**, 123-131		1
47	Successful treatment with narrowband ultraviolet B phototherapy of burn-induced leucoderma. *British Journal of Dermatology*, **2018**, 178, e327	4	1
46	Not too dark, not too light, the quest for skin, that's just right. *Indian Journal of Dermatology, Venereology and Leprology*, **2014**, 80, 387-8	0.8	1

45	Evaluation of the psychosocial impact of a Social Interaction Skills Training (SIST) workshop for patients with vitiligo: A pilot study. *Journal of the American Academy of Dermatology*, **2020**, 83, 645-647	4.5	1
44	Other Therapies in Vitiligo **2018**, 141-150		1
43	Management Issues for Vitiligo in Children and Pregnant Women **2018**, 427-438		1
42	Classification and Clinical Features of Vitiligo **2018**, 33-47		1
41	Suction Blister Epidermal Grafting **2018**, 225-239		1
40	Thin and Ultra-Thin Skin Grafts for Vitiligo **2018**, 241-248		1
39	Micropigmentation **2018**, 451-457		1
38	Camouflage in Vitiligo **2018**, 459-467		1
37	The call to action to increase racial and ethnic diversity in dermatology: A retrospective, cross-sectional study to monitor progress. *Journal of the American Academy of Dermatology*, **2021**,	4.5	0
36	UVA-Based Phototherapy **2018**, 105-112		0
35	Evaluation and Treatment of the Psychosocial Burden of Vitiligo **2018**, 61-67		0
34	Smash Grafting **2018**, 261-265		0
33	Long-Term Results of Non-Cultured Epidermal Cellular Grafting in Vitiligo **2018**, 299-302		
32	Non-Cultured Extracted Follicle Outer Root Sheath Cell Suspension Transplantation **2018**, 293-298		
31	Simplified Non-Cultured Cellular Grafting **2018**, 303-308		
30	Novel Methods of Preparing Epidermal Cell Suspension for Transplantation in Vitiligo **2018**, 309-315		
29	Application of Lasers for Abrasion in Transplantation Procedures for Vitiligo **2018**, 351-355		
28	Cell Delivery on Recipient Skin **2018**, 357-361		

27 Understanding the Mechanisms of Repigmentation in Vitiligo **2018**, 27-32

26 Melanocyte and Melanogenesis **2018**, 9-13

25 Treatment of Leukoderma by Transplantation of Basal Cell Layer Suspension **2018**, 279-291

24 Combination Treatments for Vitiligo **2018**, 439-450

23 Management of Vitiligo **2018**, 317-322

22 Depigmentation Treatment for Vitiligo **2018**, 469-473

21 Response to SAssessment of vitiligo severity: patient-reported estimates are not accurateS Reply from authors. *British Journal of Dermatology*, **2015**, 173, 1340-1 4

20 Disorders of Hyperpigmentation **2017**, 197-214

19 Melasma **2014**, 27-31

18 The Concept of Stability of Vitiligo and Stabilization Therapies **2018**, 81-90

17 Targeted Phototherapy in Vitiligo **2018**, 113-121

16 History and Chronology of Development of Surgical Therapies for Vitiligo **2018**, 171-183

15 Classification of Surgical Therapies in Vitiligo **2018**, 193-207

14 Topical Glucocorticoids, Topical Calcineurin Inhibitors, and Topical Vitamin D3 Analogs **2018**, 133-140

13 Patient Selection, Pre- and Postoperative Information in Surgical Therapies for Vitiligo **2018**, 185-191

12 Pathogenesis of Vitiligo **2018**, 19-26

11 Minigrafting for Vitiligo **2018**, 209-224

10 Treatment of Leukoderma by Transplantation of Ultra-Thin Epidermal Sheets Using a Motorized Dermatome **2018**, 249-256

List of Publications

9 Surgical Treatments of Leukodermas Other Than Vitiligo Vulgaris **2018**, 407-415

8 Mesh Grafts for Vitiligo **2018**, 257-260

7 Therapeutic Needling and Needling Micrografting **2018**, 267-271

6 Complications and Limitations of Melanocyte Transplantation **2018**, 273-277

5 Treatment of Leukoderma by Transplantation of Cultured Autologous Melanocytes **2018**, 323-335

4 Transplantation of In-Vitro-Cultured Epithelial Grafts for Vitiligo and Piebaldism **2018**, 337-350

3 Safety Concerns in Transplantation of In-Vitro-Cultured Cellular Grafts **2018**, 363-367

2 Surgical Management of Vitiligo of Lips, Eyelids, and Genitals **2018**, 369-388

1 Surgical Management of Acral Vitiligo **2018**, 389-399